Tao Yang1, Qi Zheng2,3, Hui Zhao2, Qiu-Xia Zhang2, Ming Li2, Fang Qi2, Kang-Ning Li1, Ling Fang2, Lei Wang4, Yong-Ping Fan5. 1. Department of Traditional Chinese Medicine, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100050, China. 2. School of Traditional Chinese Medicine, Capital Medical University, Beijing, 100059, China. 3. Department of Oncology, Guang'anmen Hospital of China Academy of Chinese Medical Sciences, Beijing, 100053, China. 4. School of Traditional Chinese Medicine, Capital Medical University, Beijing, 100059, China. tmwangl@ccmu.edu.cn. 5. Department of Traditional Chinese Medicine, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100050, China. yongpingf@hotmail.com.
Abstract
OBJECTIVE: To study the effects of Bushen Yisui Capsule (, BSYSC) on the oligodendrocyte lineage genes (Olig) 1 and Olig2 in C57BL/6 mice with experimental autoimmune encephalomyelitis (EAE) in order to explore the remyelination effect of BSYSC. METHODS: The mice were randomly divided into normal control (NC), EAE model (EAE-M), prednisone acetate (PA, 6 mg/kg), BSYSC high-dose (3.02 g/kg) and BSYSC low-dose (1.51 g/kg) groups. The mice were induced by immunization with myelin oligodendrocyte glycoprotein (MOG) 35-55. The neurological function scores were assessed once daily. The pathological changes in mice brains were observed with hematoxylin-eosin (HE) staining and transmission electron microscope (TEM). The protein expressions of myelin basic protein (MBP), Olig1 and Olig2 in brains were measured by immunohistochemistry. The mRNA expressions of Olig1 and Olig 2 was also determined by quantitative real-time polymerase chain reaction. RESULTS: Compared with the EAE-M mice, (1) the neurological function scores were significantly decreased in BSYSC-treated mice on days 22 to 40 (P<0.01); (2) the inflammatory cells and demyelination in brains were reduced in BSYSC-treated EAE mice; (3) the protein expression of MBP was markedly increased in BSYSC-treated groups on day 18 and 40 respectively (P<0.05 or P<0.01); (4) the protein expression of Olig1 was increased in BSYSC (3.02 g/kg)-treated EAE mice on day 40 (P<0.01). Protein and mRNA expression of Olig2 was increased in BSYSC-treated EAE mice on day 18 and 40 (P<0.01). CONCLUSION: The effects of BSYSC on reducing demyelination and promoting remyelination might be associated with the increase of Olig1 and Olig2.
OBJECTIVE: To study the effects of Bushen Yisui Capsule (, BSYSC) on the oligodendrocyte lineage genes (Olig) 1 and Olig2 in C57BL/6 mice with experimental autoimmune encephalomyelitis (EAE) in order to explore the remyelination effect of BSYSC. METHODS: The mice were randomly divided into normal control (NC), EAE model (EAE-M), prednisone acetate (PA, 6 mg/kg), BSYSC high-dose (3.02 g/kg) and BSYSC low-dose (1.51 g/kg) groups. The mice were induced by immunization with myelin oligodendrocyte glycoprotein (MOG) 35-55. The neurological function scores were assessed once daily. The pathological changes in mice brains were observed with hematoxylin-eosin (HE) staining and transmission electron microscope (TEM). The protein expressions of myelin basic protein (MBP), Olig1 and Olig2 in brains were measured by immunohistochemistry. The mRNA expressions of Olig1 and Olig 2 was also determined by quantitative real-time polymerase chain reaction. RESULTS: Compared with the EAE-M mice, (1) the neurological function scores were significantly decreased in BSYSC-treated mice on days 22 to 40 (P<0.01); (2) the inflammatory cells and demyelination in brains were reduced in BSYSC-treated EAE mice; (3) the protein expression of MBP was markedly increased in BSYSC-treated groups on day 18 and 40 respectively (P<0.05 or P<0.01); (4) the protein expression of Olig1 was increased in BSYSC (3.02 g/kg)-treated EAE mice on day 40 (P<0.01). Protein and mRNA expression of Olig2 was increased in BSYSC-treated EAE mice on day 18 and 40 (P<0.01). CONCLUSION: The effects of BSYSC on reducing demyelination and promoting remyelination might be associated with the increase of Olig1 and Olig2.
Authors: Jeff Cai; Ying Chen; Wen-Hui Cai; Edward C Hurlock; Heng Wu; Steven G Kernie; Luis F Parada; Q Richard Lu Journal: Development Date: 2007-04-11 Impact factor: 6.868
Authors: Lucia M Whitman; Caroline A Blanc; Chris S Schaumburg; David H Rowitch; Thomas E Lane Journal: Exp Neurol Date: 2012-03-17 Impact factor: 5.330
Authors: Jingya Zhang; Elisabeth G Kramer; Sean Mahase; Dipankar J Dutta; Virginie Bonnamain; Azeb T Argaw; Gareth R John Journal: Mt Sinai J Med Date: 2011 Mar-Apr
Authors: Anneke Van der Walt; Helmut Butzkueven; Scott Kolbe; Mark Marriott; Estella Alexandrou; Melissa Gresle; Gary Egan; Trevor Kilpatrick Journal: Pharmacol Ther Date: 2010-02-01 Impact factor: 12.310
Authors: Katie Lidster; Samuel J Jackson; Zubair Ahmed; Peter Munro; Pete Coffey; Gavin Giovannoni; Mark D Baker; David Baker Journal: PLoS One Date: 2013-11-04 Impact factor: 3.240